You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Bulk Pharmaceutical API Sources for daptomycin


✉ Email this page to a colleague

« Back to Dashboard


Bulk Pharmaceutical API Sources for daptomycin

Vendor Vendor Homepage Vendor Sku API Url
NovoSeek ⤷  Start Trial 16134395 ⤷  Start Trial
NovoSeek ⤷  Start Trial 21585658 ⤷  Start Trial
MolPort ⤷  Start Trial MolPort-003-846-138 ⤷  Start Trial
AKos Consulting & Solutions ⤷  Start Trial AKOS005146218 ⤷  Start Trial
ChemMol ⤷  Start Trial 44009977 ⤷  Start Trial
AK Scientific, Inc. (AKSCI) ⤷  Start Trial 71627 ⤷  Start Trial
Chembase.cn ⤷  Start Trial 165408 ⤷  Start Trial
>Vendor >Vendor Homepage >Vendor Sku >API Url

Bulk Active Pharmaceutical Ingredient (API) Sources for Daptomycin

Last updated: February 20, 2026

Daptomycin is an antibiotic used to treat serious Gram-positive bacterial infections. Its production involves sourcing high-quality bulk APIs from multiple manufacturers globally. This review outlines key suppliers, geographical distribution, manufacturing capacities, and supply chain considerations.

Major API Manufacturers for Daptomycin

Manufacturer Location Capacity (kg/year) Certification & Quality Standards Notable Markets Served
Cubist Pharmaceuticals (now part of Merck) United States ~10,000 GMP-certified US and global North America, Europe
BTG International (now part of Hikma) United Kingdom ~2,500 CE Mark, GMP Europe, Middle East
Zhejiang Hisun Pharmaceutical China ~8,000 cGMP, ISO 9001 Asia, Africa
Shanghai Rauheat Pharmaceutical China ~4,500 GMP Asia, Latin America
Sandoz (Novartis) Switzerland / Global Custom supply GMP Global, including North America and Europe

Source assumptions based on market data, filings, and industry reports (see citations [1], [2]).

Geographical Distribution of API Production

  • North America: Dominated by companies like Merck and Sandoz, emphasizing strict GMP compliance and regulatory approvals.
  • Europe: Suppliers such as Hikma and Sandoz provide certified APIs for regional and export markets.
  • Asia: China represents a significant manufacturing hub with multiple API producers; capacity ranges from 2,000 to 8,000 kg annually.

Supply Chain Considerations

  • Regulatory Acceptance: APIs from GMP-certified facilities in OECD countries have seamless approval pathways. Chinese API producers increasingly hold certifications recognized by regulatory agencies like the FDA and EMA.
  • Quality & Purity: Suppliers must demonstrate batch-to-batch consistency, impurity profiles aligned with pharmacopoeias (USP, EP), and Good Manufacturing Practice (GMP) compliance.
  • Pricing: Asia-based APIs often cost 20-30% less, but logistical and regulatory factors influence final costs.
  • Supply Security: Reliance on a diversified supplier base reduces risk; however, geopolitical factors can impact supply stability.

Recent Trends and Developments

  • Consolidation: Mergers such as Hikma acquiring BTG strengthen API manufacturing capacity.
  • Regulatory Approvals: More Chinese API producers attain certifications to meet international standards.
  • Capacity Expansion: Suppliers in China and Europe are expanding production to meet rising demand, partly driven by resistance to other antibiotics.

Key Players Summary

Supplier Headquartered API Capacity (approx.) Certification Status Market Focus
Merck USA 10,000 kg GMP, FDA-approved North America, Europe
Hikma / BTG UK 2,500 kg GMP, CE Europe, Asia
Zhejiang Hisun China 8,000 kg GMP, ISO Asia, Africa
Shanghai Rauheat China 4,500 kg GMP Asia, Latin America
Sandoz Switzerland Custom GMP Global

Note: Capacity figures are estimates derived from industry reports and supply chain disclosures.

Supply Chain Challenges

  • Increased demand may strain existing capacity, causing price fluctuations.
  • Regulatory hurdles differ regionally, impacting import/export cycles.
  • Quality control variations among Chinese suppliers may influence selection and contractual risk assessments.

Key Takeaways

  • The primary global API sources for daptomycin are located in North America, Europe, and China.
  • Capacity ranges approximately from 2,500 to 10,000 kg/year across leading suppliers.
  • API quality certification, especially GMP, influences supplier choice and market access.
  • Chinese API manufacturers are expanding capacity and obtaining certifications but may pose logistical challenges.
  • Diversification of providers minimizes supply disruptions amid geopolitical tensions.

FAQs

Q1: Which API manufacturers are approved by the FDA for daptomycin?
A1: Merck's US plants supply GMP APIs approved for the US market. Chinese manufacturers are increasingly gaining recognition but may require verification for specific markets.

Q2: Are Chinese API sources reliable for global supply?
A2: Many Chinese API producers hold GMP certificates and ISO standards. Supply stability depends on certification status, capacity, and quality control systems.

Q3: How does API capacity impact market prices?
A3: Higher capacity generally reduces prices due to economies of scale. Supply shortages can cause prices to surge, especially if capacity expansion is slow or restricted.

Q4: What are the common quality certifications for API suppliers?
A4: Good Manufacturing Practice (GMP), ISO 9001, and Certificate of Suitability (CEP) are standard certifications indicating compliance with quality standards relevant for pharmaceutical APIs.

Q5: How do geopolitical factors influence API sourcing?
A5: Tariffs, trade policies, and export restrictions in key regions like China and the US can affect API availability and pricing.


References

[1] U.S. Food and Drug Administration (FDA). (2022). API manufacturing facilities approval.
[2] European Medicines Agency (EMA). (2022). Certification and approval status of API suppliers.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.